Shire executive responsible for drug-maker's Lexington campus has quietly relocated to Paris - Innovation Economy - Boston.com
Shire executive responsible for drug-maker's Lexington campus has quietly relocated to Paris
Sylvie Gr�goire, a long-time fixture of the New England biotech scene and president of Shire's Human Genetic Therapies business in Lexington, quietly moved to Paris over the summer. Gr�goire now spends about one week a month at the company's expansive research and manufacturing campus in Lexington, which is one of the state's biggest life sciences sites, with 1250 employees.
The main reason for Gr�goire's move seems to have been personal: her husband, John Alam, left his job as chief medical officer at Vertex Pharmaceuticals earlier this year to run a unit of Sanofi in Paris called the "Therapeutic Strategic Area for Diseases of Aging."
But Jessica Cotrone, director of corporate communications at Shire, adds that since Gr�goire is part of the senior leadership team at the company, it makes sense for her to be closer to the company's headquarters in Britain and its European hub in Nyon, Switzerland. (Shire's office in Paris is small, and primarily focused on sales and marketing.) Cotrone says that when Gr�goire isn't on-site in Lexington, Bill Ciambrone, the head of Shire's manufacturing operations there, serves as acting site head. Last month, Shire finished its latest construction project in Lexington, a lab building at 200 Shire Way. By January, the company will have moved all of its Kendall Square employees out to Lexington, Cotrone says. Before joining Shire, Gr�goire was an executive at Biogen and Merck, and CEO of the New Hampshire start-up GlycoFi (which Merck acquired.)
Shire HGT makes drugs for rare diseases, including several which compete directly with Sanofi's Genzyme division, headquartered in Cambridge.
Shire executive responsible for drug-maker's Lexington campus has quietly relocated to Paris - Innovation Economy - Boston.com
Shire executive responsible for drug-maker's Lexington campus has quietly relocated to Paris
Sylvie Gr�goire, a long-time fixture of the New England biotech scene and president of Shire's Human Genetic Therapies business in Lexington, quietly moved to Paris over the summer. Gr�goire now spends about one week a month at the company's expansive research and manufacturing campus in Lexington, which is one of the state's biggest life sciences sites, with 1250 employees.
The main reason for Gr�goire's move seems to have been personal: her husband, John Alam, left his job as chief medical officer at Vertex Pharmaceuticals earlier this year to run a unit of Sanofi in Paris called the "Therapeutic Strategic Area for Diseases of Aging."
But Jessica Cotrone, director of corporate communications at Shire,
 adds that since Gr�goire is part of the senior leadership team at the company, it makes sense for her to be closer to the company's headquarters in Britain and its European hub in Nyon, Switzerland. (Shire's office in Paris is small, and primarily focused on sales and marketing.) Cotrone says that when Gr�goire isn't on-site in Lexington, Bill Ciambrone, the head of Shire's manufacturing operations there, serves as acting site head. Last month, Shire finished its latest construction project in Lexington, a lab building at 200 Shire Way. By January, the company will have moved all of its Kendall Square employees out to Lexington, Cotrone says. Before joining Shire, Gr�goire was an executive at Biogen and Merck, and CEO of the New Hampshire start-up GlycoFi (which Merck acquired.)
Shire HGT makes drugs for rare diseases, including several which compete directly with Sanofi's Genzyme division, headquartered in Cambridge.